ArticlePLoS neglected tropical diseases2009
Novel vaccines to human rabies.
Article in PLoS neglected tropical diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 93 citations in OpenAlex.
- Rabies virus large protein-derived T-cell immunogen facilitates rapid viral clearance and enhances protection against lethal challenge in mice.Communications medicine · 2025Article
- General public knowledge, attitudes, and practices about rabies and associated factors in Gomma district of Jimma zone, southwestern Ethiopia.PLoS neglected tropical diseases · 2024Article
- Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques.NPJ vaccines · 2024Article
- Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization.Vaccines · 2023Review
- Rabies prevention practices and associated factors among household heads in Bure Zuria district, North West Ethiopia.Scientific reports · 2022Article
- Colloidal Manganese Salt Improves the Efficacy of Rabies Vaccines in Mice, Cats, and Dogs.Journal of virology · 2021Article
- Production of Rabies VLPs in Insect Cells by Two Monocistronic Baculoviruses Approach.Molecular biotechnology · 2021Article
- Virus-Like Vesicles Based on Semliki Forest Virus-Containing Rabies Virus Glycoprotein Make a Safe and Efficacious Rabies Vaccine Candidate in a Mouse Model.Journal of virology · 2021Article
- Quantitative characterization of the B cell receptor repertoires of human immunized with commercial rabies virus vaccine.Human vaccines & immunotherapeutics · 2021Article
- Outer membrane proteins ofClinical and experimental vaccine research · 2021Article
- The COVID-19 Vaccine Landscape.Advances in experimental medicine and biology · 2021Review
- Optimization and validation of a blocking ELISA for quantitation of anti-rabies immunoglobulins in multispecies sera.Applied microbiology and biotechnology · 2020Article
- Incorporating B cell activating factor (BAFF) into the membrane of rabies virus (RABV) particles improves the speed and magnitude of vaccine-induced antibody responses.PLoS neglected tropical diseases · 2019Article
- Review
- An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs.PLoS neglected tropical diseases · 2016Article
- Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis.EMBO molecular medicine · 2016Article
- Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.Molecular biotechnology · 2015Review
- Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs.Frontiers in microbiology · 2015Article
- Knowledge, attitudes and practices (KAP) about rabies prevention and control: a community survey in Tanzania.PLoS neglected tropical diseases · 2014Article
- Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.The Journal of infectious diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rabies, the most fatal of all infectious diseases, remains a major public health problem in developing countries, claiming the lives of an estimated 55,000 people each year. Most fatal rabies cases, with more than half of them in children, result from dog bites and occur among low-income families in Southeast Asia and Africa. Safe and efficacious vaccines are available to prevent rabies. However, they have to be given repeatedly, three times for pre-exposure vaccination and four to five times for post-exposure prophylaxis (PEP). In cases of severe exposure, a regimen of vaccine combined with a rabies immunoglobulin (RIG) preparation is required. The high incidence of fatal rabies is linked to a lack of knowledge on the appropriate treatment of bite wounds, lack of access to costly PEP, and failure to follow up with repeat immunizations. New, more immunogenic but less costly rabies virus vaccines are needed to reduce the toll of rabies on human lives. A preventative vaccine used for the immunization of children, especially those in high incidence countries, would be expected to lower fatality rates. Such a vaccine would have to be inexpensive, safe, and provide sustained protection, preferably after a single dose. Novel regimens are also needed for PEP to reduce the need for the already scarce and costly RIG and to reduce the number of vaccine doses to one or two. In this review, the pipeline of new rabies vaccines that are in pre-clinical testing is provided and an opinion on those that might be best suited as potential replacements for the currently used vaccines is offered.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.